It's a bit premature for congratulations. The stock didn't exactly take off on the news. The differentiation with Linzess was the tolerability/safety. The FDA somehow managed to put a damper on that. This should probably be the first in class drug everyone tries first. The problem is a lot of physicians are going to be influenced by the label. Maybe the company will decide they have to partner or sell now.
News 
Market Data 
Discover 
